Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

• Main Authors: Helen L. Stacey (Author), Jeffrey Rosen (Author), James T. Peterson (Author), Angela Williams-Diaz (Author), Vanita Gakhar (Author), Tina M. Sterling (Author), Camilo J. Acosta (Author), Katrina M. Nolan (Author), Jianing Li (Author), Alison Pedley (Author), Patrice Benner (Author), Chitrananda Abeygunawardana (Author), Michael Kosinski (Author), William J. Smith (Author), Hari Pujar (Author), Luwy K. Musey (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate vaccine (PCV13) plus 2 additional serotypes (22F...